A Study of Efficacy and Safety of Lanreotide Autogel/Depot 120 mg plus BSC vs Placebo plus BSC for Tumor Control in Subjects with Well-Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (15079 A-US-52030-328)

A Study of Efficacy and Safety of Lanreotide Autogel/Depot 120 mg plus BSC vs Placebo plus BSC for Tumor Control in Subjects with Well-Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (15079 A-US-52030-328)

Trial Category:
Lung
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members